{"name": "Cellceutix",
 "permalink": "cellceutix",
 "crunchbase_url": "http://www.crunchbase.com/company/cellceutix",
 "homepage_url": "http://www.cellceutix.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@cellceutix.com",
 "phone_number": "978-633-3623",
 "description": "",
 "created_at": "Wed Feb 16 03:32:47 UTC 2011",
 "updated_at": "Fri May 11 03:43:12 UTC 2012",
 "overview": "\u003Cp\u003ECellceutix Corporation is an emerging bio-pharmaceutical company in the business of developing small molecule therapies in areas of unmet medical need. Our primary efforts are in cancer and inflammatory disease. We intend to spend most of our time initially on our lead product, Kevetrin, which is being developed for drug-resistant cancers. We\u0026#8217;ve recently announced some exciting results in animal models of multi-drug resistant lung cancer. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       40],
      "assets/images/resized/0012/2257/122257v1-max-150x150.png"],
     [[210,
       57],
      "assets/images/resized/0012/2257/122257v1-max-250x250.png"],
     [[210,
       57],
      "assets/images/resized/0012/2257/122257v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$1M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2012/05/07/daily42-Cellceutix-gets-1M-investment-readies-for-clinical-trials.html",
    "source_description": "Cellceutix gets $1M investment, readies for clinical trials",
    "raised_amount": 1000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 5,
    "funded_day": 10,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "100 Cumming Center",
    "address2": "Suite 151-B",
    "zip_code": "01915",
    "city": "Beverly",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "its treatment for autism, KM-391, has prompted a Confidential Disclosure Agreement with an unnamed \u00e2\u20ac\u0153multi-billion dollar pharmaceutical company,\u00e2\u20ac\u009d",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 28,
    "source_url": "http://www.masshightech.com/stories/2011/03/28/daily10-Cellceutix-autism-drug-attracts-CDA.html",
    "source_text": null,
    "source_description": "Cellceutix autism drug attracts CDA",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Cellceutix",
      "permalink": "cellceutix"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        113],
       "assets/images/resized/0018/9034/189034v1-max-150x150.jpg"],
      [[250,
        188],
       "assets/images/resized/0018/9034/189034v1-max-250x250.jpg"],
      [[450,
        339],
       "assets/images/resized/0018/9034/189034v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}